The CVS Caremark formulary decision (expected early June) is the key near-term catalyst — if approved without prior authorization, it would unlock significant commercial access. Monitor for the definitive update and Q2 prescription trends. The Phase 2b CSU interim readout in Q4 2026 is a pipeline catalyst but too distant to drive near-term action.
Price Chart
Executive Summary
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/share), wider than the $33.9M loss in Q1 2025. neffy U.S. net product revenue grew 125% YoY to $17.5M. The company highlighted a CVS Caremark formulary proposal in final stages with a target July 1 effective date, completion of sales force expansion to 148 reps, and full enrollment of the Phase 2b CSU interim analysis population. Despite strong revenue growth, the net loss nearly doubled due to a 76% increase in SG&A spend to $72.2M, driven by DTC marketing investment.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue of $22.7M, up 184% YoY from $8.0M
- neffy U.S. net product revenue of $17.5M, up 125% YoY from $7.8M
- Net loss of $60.6M ($0.61/share) vs $33.9M ($0.35/share) in Q1 2025
- SG&A expenses of $72.2M, up 76% YoY from $41.1M, driven by DTC marketing
- Cash, cash equivalents and short-term investments of $201.0M as of March 31, 2026
- CVS Caremark formulary proposal in final stages; definitive update anticipated in early June
- Sales force expanded from 106 to 148 representatives
- Phase 2b CSU interim population fully enrolled; data expected Q4 2026
- Health Canada approved neffy on April 15, 2026
- More than 28,000 HCPs have prescribed neffy to date, ~50% repeat prescribers
Financial Impact
Revenue grew 184% YoY to $22.7M, but net loss widened 79% to $60.6M as SG&A spend surged 76% to $72.2M. Cash burn was $44M in Q1, leaving $201M in liquidity.
Risk Factors
- SG&A spend of $72.2M in Q1 implies ~$290M annualized run rate, which would consume cash rapidly without accelerating revenue growth
- CVS Caremark proposal may not be approved, limiting commercial access
- Net loss per share of $0.61 was 74% wider than the $0.35 loss in Q1 2025, indicating worsening bottom-line trajectory
- Cash burn of $44M in Q1 reduces runway; $201M provides ~4-5 quarters at current burn rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225055 |
| Document: spry-20260515.htm | 0001193125-26-225055 |
| Document: spry-ex99_2.htm | 0001193125-26-225055 |
| Document: 0001193125-26-225055-index-headers.html | 0001193125-26-225055 |
| Document: 0001193125-26-225055-index.html | 0001193125-26-225055 |
| Document: 0001193125-26-225055.txt | 0001193125-26-225055 |
| 8-K Data (Synthetic) | 0001193125-26-225055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers